Nimodipine in the Treatment of Probable Alzheimer’s Disease

[1]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[2]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[3]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[4]  C. Cotman,et al.  Rapid Communication: Ca2+ Channel Blockers Attenuate β‐Amyloid Peptide Toxicity to Cortical Neurons in Culture , 1994 .

[5]  A. Heyman,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1993, Neurology.

[6]  Martin R. Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[7]  R F Woolson,et al.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. , 1992, The New England journal of medicine.

[8]  F. Huff,et al.  Evaluation of HP 029 (Velnacrine Maleate) in Alzheimer's Disease a , 1991, Annals of the New York Academy of Sciences.

[9]  L. Morey,et al.  Nimodipine in the treatment of old age dementias , 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  G. Tollefson.  Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia , 1990, Biological Psychiatry.

[11]  B. Reisberg,et al.  Diagnosis and Treatment of Senile Dementia , 1989, Springer Berlin Heidelberg.

[12]  J. Traber,et al.  Pharmacological basis for the use of nimodipine in central nervous system disorders , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  Anthony F. Jorm,et al.  The prevalence of dementia: A quantitative integration of the literature , 1987, Acta psychiatrica Scandinavica.

[14]  G. Gibson,et al.  Calcium and the aging nervous system , 1987, Neurobiology of Aging.

[15]  P. Landfield.  ‘Increased calcium-current’ hypothesis of brain aging , 1987, Neurobiology of Aging.

[16]  G. Roth.  Mechanisms of Altered Hormone and Neurotransmitter Action during Aging: The Role of Impaired Calcium Mobilization , 1987, Annals of the New York Academy of Sciences.

[17]  W. Rocca,et al.  Epidemiology of clinically diagnosed Alzheimer's disease , 1986, Annals of neurology.

[18]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[19]  G. Schwartz.  Development and Validation of the Geriatric Evaluation by Relative's Rating Instrument (Gerri) , 1983, Psychological reports.

[20]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[21]  P. Roberts.  Biochemistry of Dementia , 1980 .

[22]  R. Katzman.,et al.  Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.

[23]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[24]  Herman Buschke,et al.  Selective reminding for analysis of memory and learning , 1973 .

[25]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[26]  E. Rüther,et al.  Therapeutic Results with Nimodipine in Primary Degenerative Dementia and Multi-Infarct Dementia , 1989 .

[27]  J. Bigorra,et al.  Nimodipine Treatment Improves Cognitive Functions in Vascular Dementia , 1989 .

[28]  J. Dýcka,et al.  Nimodipine for Psychogeriatric Use: Methods, Strategies, and Considerations Based on Experience with Clinical Trials , 1989 .

[29]  K. Davis,et al.  Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. , 1988, Psychopharmacology bulletin.

[30]  B. Reisberg,et al.  Stage‐specific behavioral, cognitive, and in vivo changes in community residing subjects with age‐associated memory impairment and primary degenerative dementia of the Alzheimer type , 1988 .